PAPER Ma J, Choi BR, Chung C, Min SS, Jeon WK, Han JS
SEARCH RESULTS
329939 RESULTS
Julian Pei
University of PennsylvaniaLansdale, United States
Maria Jose Sanchez Artero
PsiquiatriaGuadalajara, Spain
Does PET Tracer Reveal Severity of Parkinson's?
RESEARCH NEWS 2014-04-26 Research News In order to gauge the effectiveness of disease-modifying therapies for Parkinson’s, researchers are looking for a biomarker that measures how far a person’s disease has advanced. In the April 21 JAMA Neurology, scientists led by Kun-Ju Lin a
PAPER Hsiao IT, Weng YH, Hsieh CJ, Lin WY, Wey SP, Kung MP, Yen TC, Lu CS, Lin KJ
Correlation of Parkinson Disease Severity and 18F-DTBZ Positron Emission Tomography.
JAMA Neurol. 2014 Jun 1;71(6):758-66. PubMed: 24756323PAPER Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE
Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging.
Ann Neurol. 1996 Dec;40(6):873-84. PubMed: 9007092PAPER de la Fuente-Fernández R, Sossi V, McCormick S, Schulzer M, Ruth TJ, Stoessl AJ
Visualizing vesicular dopamine dynamics in Parkinson's disease.
Synapse. 2009 Aug;63(8):713-6. PubMed: 19391152Muscle-Boosting Therapy Fails in Phase 2 Trial for ALS
RESEARCH NEWS 2014-04-26 Research News The experimental muscle-stimulating drug Tirasemtiv was unable to improve amyotrophic lateral sclerosis (ALS) symptoms in a Phase 2 clinical trial, according to top-line data. Announced April 25 by the drug’s developer, South San Francisco-b
PAPER Shefner JM, Watson ML, Meng L, Wolff AA, Neals/Cytokinetics STUDY Team
A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):574-81. Epub 2013 Aug 19 PubMed: 23952636PAPER Winblad B, Kivipelto M, Andersen P, Johansson G, Andreasen N
[Treatment of early stages of Alzheimer's disease: New guidelines are in the pipeline].
Lakartidningen. 2013 Sep 11-17;110(37):1613. PubMed: 24163935PAPER Brown LA, Jin J, Ferrell D, Sadic E, Obregon D, Smith AJ, Tan J, Giunta B
Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).
PLoS One. 2014;9(4):e95500. Epub 2014 Apr 23 PubMed: 24759994PAPER Liu MX, Liu JG, Li H
[Chinese materia medica monomers and components research progress on treating Alzheimer's disease by targeting gamma-secretase].
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Mar;34(3):376-9. PubMed: 24758094PAPER Jung Y, Dickson DW, Murray ME, Whitwell JL, Knopman DS, Boeve BF, Jack CR Jr, Parisi JE, Petersen RC, Josephs KA
TDP-43 in Alzheimer's disease is not associated with clinical FTLD or Parkinsonism.
J Neurol. 2014 Jul;261(7):1344-8. Epub 2014 Apr 24 PubMed: 24760339PAPER Woodling NS, Wang Q, Priyam PG, Larkin P, Shi J, Johansson JU, Zagol-Ikapitte I, Boutaud O, Andreasson KI
Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling.
J Neurosci. 2014 Apr 23;34(17):5882-94. PubMed: 24760848PAPER Parra-Damas A, Valero J, Chen M, España J, Martín E, Ferrer I, Rodríguez-Alvarez J, Saura CA
Crtc1 activates a transcriptional program deregulated at early Alzheimer's disease-related stages.
J Neurosci. 2014 Apr 23;34(17):5776-87. PubMed: 24760838Current Filters
No filters selected